Value-based pricing: Incentive for innovation or zero net benefit?

PharmacoEconomics

Volumn 29, Issue 9, 2011, Pages 731-735

  Hughes, Dyfrig A ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

Decision making; Formularies; Pricing; Reimbursement

Indexed keywords

ACCURACY; COST; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; PATENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK MANAGEMENT; UNITED KINGDOM; VALUE BASED PRICING;

COSTS AND COST ANALYSIS; DRUG INDUSTRY; GREAT BRITAIN; HUMANS; NATIONAL HEALTH PROGRAMS; PHARMACEUTICAL PREPARATIONS;

EID: 80051749814     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11592570-000000000-00000     Document Type: Review

References (32)

1. Association of British Pharmaceutical Industry and the Department of Health. The Pharmaceutical Price Regulation Scheme 2009 [online].Available fromURL: Http://www. dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/docu ments/digitalasset/dh-098498.pdf [Accessed 2011 May 19]
2. Office of Fair Trading. The Pharmaceutical Price Regulation Scheme: AnOFT market study. London:OFT, 2007 [online]. Available from URL: Http://www.oft.gov.uk/shared-oft/ reports/comp-policy/oft885.pdf [Accessed 2011May 19]
3. Department of Health. A new value-based approach to the pricing of branded medicines: A consultation, 2010 [online]. Available from URL: Http://www.dh.gov.uk/en/Consult ations/Closedconsultations/DH-122760 [Accessed 2011 May 19]
4. Towse A. Value based pricing, research and development, and patient access schemes: Will the United Kingdom get it right or wrong? Br J Clin Pharmacol 2010; 70 (3): 360-6
5. Office for National Statistics. Statistical bulletin: UK business enterprise research and development 2009 [online]. Available from URL: Http://www.statistics.gov.uk/pdfdir/ berd1210.pdf [Accessed 2011 May 19]
6. Joint Formulary Committee. British national formulary. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society, 2011: 61
7. Kaplan W, Laing R. Priority medicines for Europe and the world. WHO, Department of Essential Drugs and Medicines [policy document WHO/EDM/PAR/2004.7]. Geneva: WHO, 2004 [online]. Available fromURL: Http://whqlibdoc. who.int/hq/2004/WHO-EDM-PAR-2004.7.pdf [Accessed 2011 May 19]
8. Webb DJ, Walker A. Value-based pricing of drugs in the UK. Lancet 2007; 369 (9571): 1415-6
9. Claxton K. OFT, VBP: QED? Health Econ 2007 Jun; 16 (6): 545-58
10. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: What it is and what that means. Pharmacoeconomics 2008; 26 (9): 733-44
11. Sculpher S, Claxton K, Martin S, et al. Methods for estimation of the NICE cost-effectiveness threshold. Medical Research Council Methodology Research Programme [online]. Available from URL: Http://www.york.ac.uk/che/ research/teams/teehta/projects/methodological-research/work shop-held-at- imperial-college-london/ [Accessed 2011May 19]
12. Martin S, Rice N, Smith PC. Does health care spending improve health outcomes? Evidence from English programme budgeting data. J Health Econ 2008; 27: 826-42
13. Martin S, Rice N, Smith PC. The link between health spending and health outcomes for the new English primary care trusts. London: The Health Foundation, 2009
14. HM Treasury. Public expenditure by country, region and function [online]. Available from URL: Http://www.hm-treasury. gov.uk/d/pesa-2010-chapter9.pdf [Accessed 2011 May 19]
15. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 [online]. Available from URL: Http://www.nice.org. uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 2011 May 19]
16. Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ 2010; 11: 195-203
17. Williamson S. Patient access schemes for high-cost cancer medicines. Lancet Oncol 2010; 11: 111-2
18. Raftery J. Multiple sclerosis risk sharing scheme: A costly failure. BMJ 2010; 340: C1672
19. Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: An opportunity not to be missed? BMJ 2008; 336 (7638): 251-4
20. Claxton K, Sculpher M, Carroll S. Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS [Centre for Health Economics Research Paper 60]. York: University of York, 2011 [online]. Available from URL: Http://www.york.ac.uk/media/che/ documents/papers/researchpapers/CHERP60.pdf [Accessed 2011 May 19]
21. Hawkins N, Scott DA. Reimbursement and value-based pricing: Stratified cost-effectiveness analysis may not be the last word. Health Econ 2011; 20: 688-98
22. National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. London: NICE, 2009 [online]. Available fromURL: Http://www.nice. org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf [Accessed 2011 May 19]
23. NHS Health and Social Care Information Centre. Use of NICE appraised medicines in the NHS in England: 2009, experimental statistics. London: Prescribing Support Unit, 2009 [online]. Available from URL: Http://www.ic.nhs.uk/ webfiles/publications/007-Primary-Care/niceappmed0910/ NICE-bulletin-2009.pdf [Accessed 2011 May 19]
24. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: Are they a good thing? Br J Clin Pharmacol 2010; 70 (3): 335-41
25. Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 2010; 70 (3): 346-9
26. All Wales Medicines Strategy Group. Guidelines for appraising medicines. 2011 [online]. Available from URL: Http://www.wales.nhs.uk/sites3/Documents/371/ Guidelines% 20for%20appraising%20medicines.pdf [Accessed 2011 May 19]
27. Hughes DA, Ferner RE. New drugs for old: Disinvestment and NICE. BMJ 2010; 340: C572
28. Ferner RE, Hughes DA, Aronson JK. NICE and new: Appraising innovation. BMJ 2010; 340: B5493
29. Walker A, Booth C, Brown A, et al. How much good do new medicines do? [abstract]. Basic Clin Pharmacol 2009; 105 Suppl. 1: O23
30. HM Treasury. Part IIB: The taxation of innovation and intellectual property. Corporate tax reform: Delivering a more competitive system, 2010 [online]. Available from URL: Http://www.hm-treasury.gov.uk/d/corporate-tax- reform-part2b-innovation-and-intellectual-property.pdf [Accessed 2011 May 19]
31. GlaxoSmithKline. Government patent box proposals' transform' UK attractiveness for investment [media release] London: GlaxoSmithKline, 2010 Nov 29 [online]. Available from URL: Http://www.gsk.com/media/pressreleases/2010/ 2010-pressrelease-10124.htm [Accessed 2011 May 19]
32. Kesselheim AS. Using market-exclusivity incentives to promote pharmaceutical innovation. N Engl J Med 2010; 363 (19): 1855-62